IMCAS Academy

Introduction
Program
Speakers
Sponsor list
Accreditation

GO BACK

IMCAS World Congress 2019
Program

FOCUS ON S085

Melasma: change the color of your skin (in collaboration with SMD)

Partner of the session

SMD

Société Marocaine de Dermatologie

Morocco

Focus program

Room: Amphi Havane (level 3)
Date: Thursday 31 January 2019 at 14:00 to 15:00
Format: FOCUS SESSION > lectures covering a major topic of the congress

Chair

Dr Mukta SACHDEV

Dermatologist

India

Lectures of the session

Hours	Speakers	Lecture title	Abstract	Number
14:17	Dr Behrooz KASRAEE	Skin depigmenting agent: what's new (Cysteamine and others)?	View	78633
14:29	Prof Philippe HUMBERT	Benefits of oral supplementation for melasma		78635
14:41	Prof Desmond J TOBIN	Modulation of skin pigmentation with topicals	View	71531

Go to previous room (Amphi Bordeaux (level 3))

Go to next session

Recommended sessions

Pigmentation

Melasma

Vitiligo

Cosmeceuticals

Topical therapies

Dr Behrooz KASRAEE

Dermatologist

France

Other author(s) :

Skin depigmenting agent: what's new (Cysteamine and others)?

Objectives: Melasma and post-inflammatory hyperpigmentation (PIH) are frequent skin hyperpigmentary disorders which can present therapeutic challenges for the clinician. The therapeutic armamentarium against melasma and PIH is being significantly changed during the past years mainly due to the safety issues regarding the gold standard treatment, hydroquinone followed by its ban in several countries and on the other hand the emerge of depigmenting molecules with a better safety profile into the market.

Introduction: In this presentation, new therapeutic options for melasma and PIH as well as their safety and efficacy profiles will be presented. Some oral and parenteral skin depigmenting agents (e.g. tranexamic acid) as well as biogenic depigmenting compounds (e.g. L-cysteamine) will be discussed.

Results: Cysteamine hydrochloride is known for its potent depigmenting effect since 1960's when Chavin tested it through injecting cysteamine into the black goldfish skin (1). A few years later, different in vivo studies showed the higher depigmenting efficacy of this molecule compared to hydroquinone (2). Superiority to hydroquinone was recently confirmed in vitro (3). However, cysteamine has never been utilizable in human mainly due to the very offensive odor it produced in topical products. Results for a comparative study with Kligman formula will be presented.

Conclusion: Cysteamine is biologically produced in mammalian cells and serves as an intracellular anti-oxidant. This molecule is FDA approved as eye-drops and as an oral medication and has a long history of safety for human use. The anti-mutagenic and anti-carcinogenic effects of cysteamine are previously shown in numerous studies. With its high efficacy and safety profiles, topical cysteamine has a higher benefit/risk ratio compared to hydroquinone and might serve as a new safe and effective skin depigmenting agent for the treatment of hyperpigmentary disorders such as melasma.

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): beyond cosmeceuticals SA

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): beyond cosmeceuticals SA

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): beyond cosmeceuticals SA

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: beyond cosmeceuticals SA

Prof Philippe HUMBERT

Dermatologist

France

Other author(s) :

Benefits of oral supplementation for melasma

Prof Desmond J TOBIN

PhD - Research

Ireland

Other author(s) :

Modulation of skin pigmentation with topicals

Objectives: The literature is full of reports claiming to describe inhibitors (and more recently stimulators) of melanin synthesis and transfer. This talk will provide understanding of how modulation of skin pigmentation can be approached from several levels in terms of melanin synthesis (amount and subtype), transfer to keratinocytes, distribution within different epidermis strata and ultimate melanin fate. This talk with review our recent work in this area.

Introduction: Melanin is synthesized by melanocytes in the epidermis basal layer, and when transferred to keratinocytes is the key ultraviolet radiation-protective biopolymer responsible for skin pigmentation. However, most melanin is seen only in the proliferative basal layer and only sparsely above this. The latter has been explained (without convincing evidence) as 'melanin degradation' in suprabasal layers. We have recently re-evaluated how melanin is distribution in human epidermis under normal and stress conditions. Our new understanding allows us to reassess how melanin levels can be modulated.

Materials / method: Using skin tissues derived from normal healthy individuals of different skin phototype, and cell cultures derived from these tissues for standard bioscience experimental analysis.

Results: We have recently revisited the need to develop a new generation of safe topical ingredients, with cosmetic and therapeutic potential (vitiligo, Pityriasis alba etc.). We have identified a novel way to modulate the epidermal-melanin unit function, by mimicking a growth factor that stimulates melanogenesis and melanin transfer. Specifically, we have identified small peptide mimics of BMP6, by interrogating the binding site of BMP6 with its receptor. After cytotoxicity assessment in vitro, we have evaluated these in aqueous-soluble and topical form using pigmented human skin equivalents.

Conclusion: Some of these peptides exhibited the ability to increase melanogenesis when topically applied in a 3-D human skin model, and we believe that this technology offers significant benefits over the currently available technology. We are currently investigating whether these molecules may be modified to have the reverse activity on this melanogenesis pathway.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

You have a question?

Quickly find your answer in our FAQ

Congresses

IMCAS Americas
IMCAS Asia
IMCAS World Congress

About

Company
Privacy Policy
Legal information

Academy

Home
Courses
Webinars
Explore
Blog

Grant

Educational grant

Get in touch

Username/Email

Password

Keep me logged in

Forgot password ? Do not have an account yet? Sign up now

Keep me logged in

academy.Do_not_have_an_account_yet Sign up now

IMCAS World Congress 2019 Program

FOCUS ON S085

Melasma: change the color of your skin (in collaboration with SMD)

Chair

Lectures of the session

Recommended sessions

IMCAS World Congress 2019
Program